Investor Relations

We are Anchiano Therapeutics, a pivotal-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat cancer in areas of unmet need.

Our initial program is the genetic therapy for early stage bladder cancer. Inodiftagene visteplasmid (formerly BC-819), our most advanced investigational agent, is under development as a treatment for non-muscle-invasive bladder cancer (NMIBC).

We are located in Cambridge, MA, and in Jerusalem, and are publicly traded on the Nasdaq (NASDAQ: ANCN).

Scientific and Medical

Focus on discovering and developing therapies for patients with cancer in areas of unmet need

Initial program: genetic therapy for early stage bladder cancer

Utilizes technology licensed from Hebrew University

Corporate

Founded in 2004; based in Cambridge and Jerusalem

CEO (former Harvard faculty; Ariad chief medical officer) based in Cambridge, building U.S. team and infrastructure

Financial

Market capitalization: $50.5 million (end Q1 2019)

Share capitalization: 7.4 million ADSs outstanding (NASDAQ: ANCN) equivalent to 37.1 million outstanding shares

10.1 million ADSs fully diluted, equivalent to 50.5 million shares

Cash: $32 million (end Q1 2019), no debt

Stock Quote

Nasdaq

Intraday delay: 15 minutes

Stock Chart 

Intraday delay: 15 minutes

SEC Company Filings


Filing DateFormDescriptionDownload
7/8/196-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
6/18/196-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
5/28/196-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
5/22/196-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
4/24/1920-F/A[Amend] Annual and transition report of foreign private issuers [Sections 13 or 15(d)]PDF
3/25/1920-KAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]PDF
3/14/196-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
3/12/196-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
2/14/196-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
2/13/19424B4Prospectus [Rule 424(b)(4)]PDF
2/12/196-KReport of foreign issuer [Rules 13a-16 and 15d-16]PDF
2/11/19F-1/A[Amend] Registration statement for certain foreign private issuersPDF
2/8/198-A12BRegistration of securities [Section 12(b)]PDF
2/8/19F-1/A[Amend] Registration statement for certain foreign private issuersPDF
2/7/19F-1/A[Amend] Registration statement for certain foreign private issuersPDF
1/30/19F-1/A[Amend] Registration statement for certain foreign private issuersPDF
1/7/19F-1Registration statement for certain foreign private issuers PDF
Anchiano Therapeutics Ltd. CIK#: 0001534248 (see all company filings)

Contact Investor Relations

Ashley Robinson, LifeSci Advisors
Email: arr@lifesciadvisors.com

Presentations

MIXiii-BIOMED 2019 | May 16, 2019 

Anchiano Biomed 20190516
Click here to download 

 

Oppenheimer 29th Annual Healthcare Conference | March 20, 2019 

Anchiano Oppenheimer 20190319
Click here to download

 

Corporate Presentation | January 2019 

Anchiano-Corporate-Presentation-TTW-20190118
Click here to download